Phaseolamin

This MedLibrary.org supplementary page on Phaseolamin is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Phaseolamin, also known as "Phase 2", is a proteinaceous inhibitor of alpha-amylase. Originally isolated from white kidney beans, the protein is now commercially produced and sold as a diet aid. It works by inhibiting the action of starch degradation enzyme alpha-amylase, so that less sugar is absorbed in the small intestine. It is only active on alpha-amylases of animal origin, and does not affect those produced by plants, bacteria or fungi.

Clinical trial results

In a clinical trial performed by Jay Udani, MD (Assistant Clinical Professor at the UCLA School of Medicine), a randomly selected group of obese subjects were given 1500 mg Phaseolamin twice daily with meals. Over the period of the eight week trial, which 27 subjects completed, the group using Phaseolamin showed an average weight loss of 3.79 pounds, compared with an average of 1.65 pounds for subjects taking a placebo. No adverse effects were observed during the trial.

References

Wikipedia content modification information:

  • This page was last modified on 2 July 2008, at 16:25.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Phaseolamin".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.